Verona Pharma plc (NASDAQ:VRNA – Get Free Report) insider Kathleen A. Rickard sold 36,248 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $1.96, for a total transaction of $71,046.08. Following the sale, the insider now directly owns 2,621,552 shares in the company, valued at $5,138,241.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Verona Pharma Stock Performance
VRNA stock traded down $0.06 during mid-day trading on Friday, hitting $15.69. The company had a trading volume of 507,336 shares, compared to its average volume of 492,899. The stock’s fifty day moving average price is $16.23 and its two-hundred day moving average price is $16.14. Verona Pharma plc has a 12 month low of $11.83 and a 12 month high of $23.81. The firm has a market cap of $1.27 billion, a PE ratio of -22.74 and a beta of 0.43. The company has a debt-to-equity ratio of 0.20, a quick ratio of 33.33 and a current ratio of 33.33.
Verona Pharma (NASDAQ:VRNA – Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.07. On average, analysts forecast that Verona Pharma plc will post -1.32 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Verona Pharma
Analysts Set New Price Targets
VRNA has been the subject of a number of recent research reports. Piper Sandler increased their price objective on Verona Pharma from $31.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, April 16th. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Verona Pharma in a research report on Friday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Verona Pharma in a report on Monday, March 4th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verona Pharma has a consensus rating of “Buy” and an average price target of $33.60.
Read Our Latest Stock Analysis on Verona Pharma
About Verona Pharma
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Articles
- Five stocks we like better than Verona Pharma
- Where to Find Earnings Call Transcripts
- Appleās Earnings Show Investors Its Strength and Its Weakness
- What is the Dow Jones Industrial Average (DJIA)?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- What is the S&P/TSX Index?
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.